Connect your AI

Cerus CERS Operating Lease Liabilities

Operating Lease Liabilities at other companies

Bio-Rad LaboratoriesBIO

$138.6M+9.7%

Protagonist TherapeuticsPTGX

$7.44M-24.1%

QuidelOrtho CorporationQDEL

$155.4M-4.8%

ADMA BiologicsADMA

$6.37M-23.3%

PaysignPAYS

$5.05M+114%

Other financials

Income statement

Revenue$53.7M+24.1%

Operating income-$354.0K+94.0%

Net income-$1.6M+78.7%

EPS (diluted)-$0.01+75.0%

Balance sheet

Cash & equivalents$27.9M+43.0%

Total debt$45.0M-43.3%

Total equity$67.6M+21.7%

Total assets$222.9M+7.8%

Cash flow

Operating cash flow-$3.0M-261%

CapEx$233.0K+108%

Free cash flow-$3.3M-243%

Valuation

Market cap$573.06M+124%

Enterprise value$590.17M+86.7%

P/S2.9×-1.0×

Profitability

Gross margin64%—

Operating margin-6.2%-2.1pp

Net margin-9.8%-2.8pp

FCF margin3.5%+1.9pp

Returns & leverage

Return on equity-15.5%-5.6pp

Debt / equity0.7×-0.8×

Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cerus's operating lease liabilities?: Cerus (CERS) reported operating lease liabilities of $9.38M in Q1 2026.
How has Cerus's operating lease liabilities changed year-over-year?: Cerus's operating lease liabilities decreased by 21.4% year-over-year, from $11.94M to $9.38M.
What is the long-term trend for Cerus's operating lease liabilities?: Over 5 years (2020 to 2025), Cerus's operating lease liabilities has grown at a -9.7% compound annual growth rate (CAGR), from $16.87M to $10.15M.
What does operating lease liabilities mean?: Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.